Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sodium‐Glucose Co‐Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Arjun Pandey, Iva Okaj, Hargun Kaur, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 17
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1498
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 361
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Stylianos Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, et al.
EP Europace (2024) Vol. 26, Iss. 4
Open Access | Times Cited: 153
Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction
Yogesh N.V. Reddy, Barry A. Borlaug, Bernard J. Gersh
Circulation (2022) Vol. 146, Iss. 4, pp. 339-357
Open Access | Times Cited: 78
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Stylianos Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, et al.
Heart Rhythm (2024) Vol. 21, Iss. 9, pp. e31-e149
Open Access | Times Cited: 78
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 31
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Stylianos Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, et al.
Journal of Interventional Cardiac Electrophysiology (2024) Vol. 67, Iss. 5, pp. 921-1072
Open Access | Times Cited: 21
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation
Stylianos Tzeis, Edward P. Gerstenfeld, Jonathan M. Kalman, et al.
Journal of Arrhythmia (2024) Vol. 40, Iss. 6, pp. 1217-1354
Open Access | Times Cited: 18
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Alireza Oraii, Jeff S. Healey, Krzysztof Kowalik, et al.
European Heart Journal (2024) Vol. 45, Iss. 10, pp. 756-774
Open Access | Times Cited: 16
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 60
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Ewald Kolesnik, Douglas S. Scherr, Ursula Rohrer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1678-1678
Open Access | Times Cited: 42
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 35
Recent Advances in Antiarrhythmic Drug Therapy
Arnela Saljic, Jordi Heijman, Dobromir Dobrev
Drugs (2023) Vol. 83, Iss. 13, pp. 1147-1160
Open Access | Times Cited: 31
Association between sodium–glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation
Akash Fichadiya, Amity E. Quinn, Flora Au, et al.
EP Europace (2024) Vol. 26, Iss. 3
Open Access | Times Cited: 14
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Moran Gvili Perelman, Rafael Y. Brzezinski, Barliz Waissengrin, et al.
Cardio-Oncology (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 11
Differing Efficacy of Dapagliflozin Versus Empagliflozin on the Risk of Incident Atrial Fibrillation in Patients With Type 2 Diabetes: A Real‐World Observation Using a Nationwide, Population‐Based Cohort
Jae-Hyun Lim, Soongu Kwak, You‐Jung Choi, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 3
Open Access | Times Cited: 11
Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects
Michiel Rienstra, Stylianos Tzeis, Karina V Bunting, et al.
EP Europace (2024) Vol. 26, Iss. 12
Open Access | Times Cited: 8
Outcomes in Atrial Fibrillation Patients with Different Clinical Phenotypes: Insights from the French Population
Ameenathul M. Fawzy, Arnaud Bisson, Lisa Lochon, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1044-1044
Open Access | Times Cited: 1
SGLT2i and Cardiovascular Events in Patients With Concomitant Atrial Fibrillation and Diabetes: A TriNetX Cohort Study
Yu–Yu Hsiao, Yun‐Yu Chen, Ming‐Jen Kuo, et al.
The Journal of Clinical Endocrinology & Metabolism (2025)
Open Access | Times Cited: 1
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation
Αndreas S. Papazoglou, Αναστάσιος Κάρτας, Dimitrios V. Moysidis, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 33
Sodium–glucose co-transporter-2 inhibitors for the prevention of atrial fibrillation: a systemic review and meta-analysis
Hongda Zhang, Lei Ding, Lijie Mi, et al.
European Journal of Preventive Cardiology (2023) Vol. 31, Iss. 7, pp. 770-779
Closed Access | Times Cited: 20
Impact of Sodium‐Glucose Cotransporter 2 Inhibitor on Recurrence After Catheter Ablation for Atrial Fibrillation in Patients With Diabetes: A Propensity‐Score Matching Study and Meta‐Analysis
Zixu Zhao, Chao Jiang, Liu He, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 24
Open Access | Times Cited: 17
Management of atrial fibrillation in older adults
Anna L. Parks, David S. Frankel, Dae Hyun Kim, et al.
BMJ (2024), pp. e076246-e076246
Closed Access | Times Cited: 7
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
Min Zhuo, Elvira D’Andrea, Julie M. Paik, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2235995-e2235995
Open Access | Times Cited: 23
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Page 1 - Next Page

Scroll to top